BetterLife Pharma Inc.
BETRF
$0.22
$0.000.14%
OTC PK
| 04/30/2026 | 01/31/2026 | 10/31/2025 | 07/31/2025 | 04/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -29.80% | -60.39% | -55.55% | -45.91% | -38.04% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -34.36% | -62.14% | -59.71% | -52.75% | -39.47% |
| Operating Income | 34.36% | 62.14% | 59.71% | 52.75% | 39.47% |
| Income Before Tax | -9.93% | 58.41% | 48.09% | 82.04% | 56.89% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -9.93% | 58.41% | 48.09% | 82.04% | 56.89% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 489.36% | -82.81% | 108.51% | 98.85% | 98.68% |
| Net Income | -8.10% | 57.70% | 56.11% | 83.70% | 61.39% |
| EBIT | 34.36% | 62.14% | 59.71% | 52.75% | 39.47% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 12.50% | 66.36% | 63.98% | 86.69% | 64.26% |
| Normalized Basic EPS | 42.00% | 71.67% | 68.51% | 75.00% | 57.26% |
| EPS Diluted | 25.98% | 67.89% | 56.09% | 80.19% | 58.36% |
| Normalized Diluted EPS | 42.00% | 71.67% | 68.51% | 75.00% | 57.26% |
| Average Basic Shares Outstanding | 19.22% | 17.73% | 16.75% | 16.10% | 12.52% |
| Average Diluted Shares Outstanding | 15.31% | 13.76% | 12.69% | 19.83% | 16.34% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |